1309684-82-9

Basic information

• Product Name: (2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-5-fluoro-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (4-carbamoylphenyl)amide
• CAS NO: 1309684-82-9
• Molecular Weight: 601.48
• Mol File: 1309684-82-9.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-5-fluoro-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (4-carbamoylphenyl)amide(CAS DataBase Reference)
• NIST Chemistry Reference: (2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-5-fluoro-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (4-carbamoylphenyl)amide(1309684-82-9)
• EPA Substance Registry System: (2'S,3'R,4'S,5'R)-6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-dimethylpropyl)-5-fluoro-2-oxo-1,2-dihydrospiro[indole-3,3'-pyrrolidine]-5'-carboxylic acid (4-carbamoylphenyl)amide(1309684-82-9)

Safety Data

• Hazardous Substances Data: 1309684-82-9(Hazardous Substances Data)

Upstream product

• 873-74-5 4-Aminobenzonitrile 
• 100487-74-9 6-Chloro-5-fluoro-1,3-dihydro-2H-indol-2-one 
• 2987-16-8 3,3-dimethylbutyrylaldehyde 
• 1219086-34-6 2-[(E)-(3,3-dimethylbutylidene)amino]acetic acid tert-butyl ester 
• 85070-48-0 2-fluoro-3-chlorobenzaldehyde 

Relevant articles and documents

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

The field of small-molecule inhibitors of protein-protein interactions is rapidly advancing and the specific area of inhibitors of the p53/MDM2 interaction is a prime example. Several groups have published on this topic and multiple compounds are in various stages of clinical development. Building on the strength of the discovery of RG7112, a Nutlin imidazoline-based compound, and RG7388, a pyrrolidine-based compound, we have developed additional scaffolds that provide opportunities for future development. Here, we report the discovery and optimization of a highly potent and selective series of spiroindolinone small-molecule MDM2 inhibitors, culminating in RO8994.